Research ArticleNuclear Oncology
Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma
Ayda M. El-Shirbiny, Henry Yeung, Massimo Imbriaco, Joseph Michaeli, Homer Macapinlac and Steven M. Larson
Journal of Nuclear Medicine August 1997, 38 (8) 1208-1210;
Ayda M. El-Shirbiny
Henry Yeung
Massimo Imbriaco
Joseph Michaeli
Homer Macapinlac


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma
Ayda M. El-Shirbiny, Henry Yeung, Massimo Imbriaco, Joseph Michaeli, Homer Macapinlac, Steven M. Larson
Journal of Nuclear Medicine Aug 1997, 38 (8) 1208-1210;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study
- Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias
- 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma
- Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
- Combined Use of 99mTc-Sestamibi and 99mTc-V-DMSA in the Assessment of Chemotherapy Effectiveness in Patients with Multiple Myeloma
- Whole-Body 18F-FDG PET Identifies High-Risk Myeloma